News archive
Showing 654 results
November 2020
-
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs ELARA results for Kymriah® in relapsed or… -
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
-
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult… -
Media Release
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media Release
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week 11 ULTIMATE is the first ever Phase IIIb…
October 2020
-
Media Release
Novartis STEP Program™ awards nearly $375,000 to patient advocacy organizations for their innovative solutions in biomarker testing; now accepting proposals for caregiving in cancer and certain blood disorders
The STEP (Solutions to Empower Patients) ProgramTM supports nonprofit organizations that deliver creative solutions to address barriers to care Five patient advocacy organizations were provided… -
Media Release
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
-
Media Release
Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
Results presented at the Migraine Trust Virtual Symposium highlight long-term benefit of Aimovig Aimovig has the longest duration of safety and efficacy trial data for any anti-CGRP pathway…
September 2020
-
Media Release
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Media Release
Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice Commitment to include…